SI21302A - Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino - Google Patents

Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino Download PDF

Info

Publication number
SI21302A
SI21302A SI200200244A SI200200244A SI21302A SI 21302 A SI21302 A SI 21302A SI 200200244 A SI200200244 A SI 200200244A SI 200200244 A SI200200244 A SI 200200244A SI 21302 A SI21302 A SI 21302A
Authority
SI
Slovenia
Prior art keywords
gas
pharmaceutical
active ingredient
amorphous active
stable
Prior art date
Application number
SI200200244A
Other languages
English (en)
Slovenian (sl)
Inventor
Rok Grahek
Andrej Bastarda
Mateja Salobir
Original Assignee
LEK farmacevtska dru�ba d.d.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32091984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI21302(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LEK farmacevtska dru�ba d.d. filed Critical LEK farmacevtska dru�ba d.d.
Priority to SI200200244A priority Critical patent/SI21302A/sl
Priority to TW092127769A priority patent/TWI320709B/zh
Priority to AU2003280361A priority patent/AU2003280361B2/en
Priority to PCT/EP2003/011265 priority patent/WO2004032920A1/en
Priority to CZ200718450U priority patent/CZ17610U1/cs
Priority to SK5006-2007U priority patent/SK5233Y1/sk
Priority to RU2005114485/15A priority patent/RU2358727C2/ru
Priority to DE60312049T priority patent/DE60312049T2/de
Priority to ES03770970T priority patent/ES2285205T3/es
Priority to UAA200504398A priority patent/UA85544C2/ru
Priority to YU20050273A priority patent/RS51819B/sr
Priority to DE20321455U priority patent/DE20321455U1/de
Priority to AT03770970T priority patent/ATE354362T1/de
Priority to MEP-2008-842A priority patent/ME00514B/me
Priority to SI200330805T priority patent/SI1608362T1/sl
Priority to US10/683,683 priority patent/US20040077708A1/en
Priority to PT03770970T priority patent/PT1608362E/pt
Priority to DK03770970T priority patent/DK1608362T3/da
Priority to EP03770970A priority patent/EP1608362B1/en
Priority to CNB2003801009910A priority patent/CN100372529C/zh
Priority to ARP030103710A priority patent/AR041588A1/es
Publication of SI21302A publication Critical patent/SI21302A/sl
Priority to DK200700025U priority patent/DK200700025U4/da
Priority to FI20070036U priority patent/FI7617U1/fi
Priority to AT0010907U priority patent/AT10424U1/de
Priority to CY20071100681T priority patent/CY1106608T1/el
Priority to US11/923,059 priority patent/US20090012150A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI200200244A 2002-10-11 2002-10-11 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino SI21302A (sl)

Priority Applications (26)

Application Number Priority Date Filing Date Title
SI200200244A SI21302A (sl) 2002-10-11 2002-10-11 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
TW092127769A TWI320709B (en) 2002-10-11 2003-10-07 Stabilized pharmaceutical composition comprising an amorphous active substance
ARP030103710A AR041588A1 (es) 2002-10-11 2003-10-10 Composicion farmaceutica estabilizada que comprende una sustancia activa amorfa
AT03770970T ATE354362T1 (de) 2002-10-11 2003-10-10 Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
US10/683,683 US20040077708A1 (en) 2002-10-11 2003-10-10 Stablized pharmaceutical composition comprising an amorphous active substance
CZ200718450U CZ17610U1 (cs) 2002-10-11 2003-10-10 Stabilizovaný farmaceutický prípravek obsahující amorfní kalcium-atorvastatin
SK5006-2007U SK5233Y1 (en) 2002-10-11 2003-10-10 Stabilized pharmaceutical preparation comprising amorphous atorvastatin calcium and method for packaging and stabilisation thereof
RU2005114485/15A RU2358727C2 (ru) 2002-10-11 2003-10-10 Стабилизированный фармацевтический препарат, включающий аморфное активное вещество
DE60312049T DE60312049T2 (de) 2002-10-11 2003-10-10 Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
ES03770970T ES2285205T3 (es) 2002-10-11 2003-10-10 Preparacion farmaceutica estable que comprende una substancia activa amorfa.
UAA200504398A UA85544C2 (ru) 2002-10-11 2003-10-10 Стабилизированный фармацевтический препарат аморфного аторвастатина кальция
YU20050273A RS51819B (sr) 2002-10-11 2003-10-10 Stabilizovani farmaceutski preparat koji sadrži amorfnu aktivnu supstancu
DE20321455U DE20321455U1 (de) 2002-10-11 2003-10-10 Stabilisiertes pharmazeutisches Erzeugnis, das einen amorphen Wirkstoff enthält
AU2003280361A AU2003280361B2 (en) 2002-10-11 2003-10-10 Stabilized pharmaceutical preparation comprising an amorphous active substance
MEP-2008-842A ME00514B (me) 2002-10-11 2003-10-10 Stabilizovani farmaceutski preparat koji sadrži amorfnu aktivnu supstancu
SI200330805T SI1608362T1 (sl) 2002-10-11 2003-10-10 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
PCT/EP2003/011265 WO2004032920A1 (en) 2002-10-11 2003-10-10 Stabilized pharmaceutical preparation comprising an amorphous active substance
PT03770970T PT1608362E (pt) 2002-10-11 2003-10-10 Preparação farmacêutica estabilizada incluindo uma substância activa amorfa
DK03770970T DK1608362T3 (da) 2002-10-11 2003-10-10 Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse
EP03770970A EP1608362B1 (en) 2002-10-11 2003-10-10 Stabilized pharmaceutical preparation comprising an amorphous active substance
CNB2003801009910A CN100372529C (zh) 2002-10-11 2003-10-10 包含无定形活性物质的稳定药物制剂
DK200700025U DK200700025U4 (da) 2002-10-11 2007-01-25 Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse
FI20070036U FI7617U1 (fi) 2002-10-11 2007-01-26 Amorfisen aktiivisen ainesosan stabiloitu farmaseuttinen valmiste
AT0010907U AT10424U1 (de) 2002-10-11 2007-02-20 Fertigarzneimittel, enthaltend ein in inertgas gelagertes, amorphes atorvastatin-ca
CY20071100681T CY1106608T1 (el) 2002-10-11 2007-05-21 Σταθεροποιημενα φαρμακευτικα σκευασματα που περιλαμβανουν μια αμορφη δραστικη ουσια
US11/923,059 US20090012150A1 (en) 2002-10-11 2007-10-24 Stablized Pharmaceutical Composition Comprising an Amorphous Active Substance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200200244A SI21302A (sl) 2002-10-11 2002-10-11 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino

Publications (1)

Publication Number Publication Date
SI21302A true SI21302A (sl) 2004-04-30

Family

ID=32091984

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200200244A SI21302A (sl) 2002-10-11 2002-10-11 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
SI200330805T SI1608362T1 (sl) 2002-10-11 2003-10-10 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200330805T SI1608362T1 (sl) 2002-10-11 2003-10-10 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino

Country Status (21)

Country Link
US (2) US20040077708A1 (cs)
EP (1) EP1608362B1 (cs)
CN (1) CN100372529C (cs)
AR (1) AR041588A1 (cs)
AT (2) ATE354362T1 (cs)
AU (1) AU2003280361B2 (cs)
CY (1) CY1106608T1 (cs)
CZ (1) CZ17610U1 (cs)
DE (2) DE60312049T2 (cs)
DK (2) DK1608362T3 (cs)
ES (1) ES2285205T3 (cs)
FI (1) FI7617U1 (cs)
ME (1) ME00514B (cs)
PT (1) PT1608362E (cs)
RS (1) RS51819B (cs)
RU (1) RU2358727C2 (cs)
SI (2) SI21302A (cs)
SK (1) SK5233Y1 (cs)
TW (1) TWI320709B (cs)
UA (1) UA85544C2 (cs)
WO (1) WO2004032920A1 (cs)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044086B2 (en) 2004-07-16 2011-10-25 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US8777011B2 (en) 2001-12-21 2014-07-15 Novartis Ag Capsule package with moisture barrier
WO2005011638A2 (en) * 2003-08-05 2005-02-10 Zentiva, A. S. Methods for the stabilization of atorvastatin
WO2005092852A1 (en) 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
EP1793815A4 (en) * 2004-09-30 2010-12-29 Reddys Lab Ltd Dr AMORPHES ATORVASTATINCALCIUM
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
US20090247603A1 (en) 2005-12-23 2009-10-01 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP1810667A1 (en) * 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
EP2182925A2 (en) * 2007-07-27 2010-05-12 Cipla Limited Pharmaceutical compositions and process for making them
US20090071855A1 (en) * 2007-09-14 2009-03-19 Bahuguna Sumit Packaging for amorphous statins and compositions thereof
EP2127628A1 (en) * 2008-05-27 2009-12-02 Ranbaxy Laboratories Limited Unit dose pack
WO2011077843A1 (ja) 2009-12-25 2011-06-30 沢井製薬株式会社 アトルバスタチン含有被覆製剤
RU2014124118A (ru) 2011-11-15 2015-12-27 Др. Редди'С Лабораторис Лтд. Фармацевтические препараты, включающие аторвастатин и глимепирид
CN102525942A (zh) * 2012-01-05 2012-07-04 金陵药业股份有限公司 一种阿托伐他汀钙肠溶微丸及其制备方法
JP6889116B2 (ja) * 2015-02-03 2021-06-18 カドモン ファーマシューティカルズ，リミティド ライアビリティ カンパニー 安定トリエンチン製剤
US10905113B2 (en) 2015-11-12 2021-02-02 Regents Of The University Of Minnesota Compositions and method for storing liquid biospecimens
EP3184103A1 (en) 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof
US11968975B2 (en) 2019-04-30 2024-04-30 Regents Of The University Of Minnesota Compositions and methods for storing liquid biospecimens

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2194418B2 (cs) * 1971-08-02 1977-01-28 Sada Pietro
DE2625164A1 (de) * 1976-06-04 1977-12-15 Goedecke Ag Fluessige oder halbfeste arzneiformen oder kosmetische zubereitungen
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE69506122D1 (de) * 1994-09-30 1998-12-24 Becton Dickinson Co Verfahren zur herstellung und verpackung von iontophoretischen pflastern und denselben, um die stabilität und die lagerstabilität zu verbessern
GB9425783D0 (en) * 1994-12-21 1995-02-22 Ethical Pharma Ltd Packaging of patches
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
SG125044A1 (en) * 1996-10-14 2006-09-29 Mitsubishi Gas Chemical Co Oxygen absorption composition
US6155454A (en) * 1997-05-03 2000-12-05 Donald C. George Pill dispenser employing a sealed pill carrier and integrated dispensing plungers
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6375956B1 (en) * 1999-07-22 2002-04-23 Drugtech Corporation Strip pack
CZ20023826A3 (cs) * 2000-06-09 2003-04-16 Lek Pharmaceuticals D. D. Stabilizovaná farmaceuticky účinná kompozice a léčivý přípravek tuto kompozici obsahující
CZ20024015A3 (cs) * 2000-06-09 2003-04-16 Lek Pharmaceutical D.D. Stabilní farmaceutický produkt a jeho formulace
US6293393B1 (en) * 2000-07-18 2001-09-25 Sdk Co., Inc. Apparatus and methods for packaging and distributing combinations of foods and beverages
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
EP1241110A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044086B2 (en) 2004-07-16 2011-10-25 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium

Also Published As

Publication number Publication date
DK200700025U4 (da) 2008-03-14
RS51819B (sr) 2011-12-31
TWI320709B (en) 2010-02-21
UA85544C2 (ru) 2009-02-10
RS20050273A (sr) 2007-06-04
FIU20070036U0 (fi) 2007-01-26
FI7617U1 (fi) 2007-09-28
AU2003280361B2 (en) 2009-02-26
US20040077708A1 (en) 2004-04-22
DK200700025U1 (da) 2007-06-08
DE20321455U1 (de) 2007-05-24
CN1703215A (zh) 2005-11-30
SK50062007U1 (en) 2009-03-05
PT1608362E (pt) 2007-05-31
DE60312049D1 (de) 2007-04-05
RU2358727C2 (ru) 2009-06-20
AU2003280361A1 (en) 2004-05-04
SI1608362T1 (sl) 2007-12-31
ATE354362T1 (de) 2007-03-15
DK1608362T3 (da) 2007-05-14
WO2004032920A1 (en) 2004-04-22
EP1608362B1 (en) 2007-02-21
TW200501947A (en) 2005-01-16
DE60312049T2 (de) 2007-10-04
EP1608362A1 (en) 2005-12-28
SK5233Y1 (en) 2009-09-07
CY1106608T1 (el) 2012-01-25
RU2005114485A (ru) 2006-01-27
AR041588A1 (es) 2005-05-26
CZ17610U1 (cs) 2007-06-18
ES2285205T3 (es) 2007-11-16
CN100372529C (zh) 2008-03-05
US20090012150A1 (en) 2009-01-08
AT10424U1 (de) 2009-03-15
ME00514B (me) 2011-10-10

Similar Documents

Publication Publication Date Title
SI21302A (sl) Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
JP4065321B2 (ja) 水分活性を調節したゼラチンカプセル剤
Narang et al. Impact of excipient interactions on solid dosage form stability
US20100172995A1 (en) Process For Preparing A Solid Pharmaceutical Composition
US20090176755A1 (en) Pharmaceutical compositions comprising an antibiotic
RS63830B1 (sr) Proces za dobijanje rastvora estra bortezomiba
RS63736B1 (sr) Rastvor bortezomiba spreman za upotrebu
SK50462005A3 (sk) Spôsoby stabilizácie atorvastatínu
EA014936B1 (ru) Фармацевтическая композиция, содержащая аморфный аторвастатин
Mahajan et al. The effect of inert atmospheric packaging on oxidative degradation in formulated granules
EP1296672A1 (en) Stable pharmaceutical product and formulation
JP2006052156A (ja) 経口投与用医薬組成物
JP2006045218A (ja) 経口投与用医薬組成物
EP1473033A1 (en) Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20121019